A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies
Latest Information Update: 29 Apr 2024
At a glance
- Drugs LP-118 (Primary)
- Indications Acute myeloid leukaemia; Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Richter's syndrome; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Newave Pharmaceuticals
- 23 Apr 2024 Planned End Date changed from 1 Aug 2024 to 1 Oct 2025.
- 23 Apr 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Oct 2025.
- 27 Mar 2023 Eligibility criteria amended from greater than equal to 18 years of age to greater than equal to 13 years of age .